Lokelma, a medication used to treat hyperkalemia, is protected by several patents. These patents have varying expiration dates, influencing when generic versions might become available.
When does Lokelma's patent exclusivity expire?
The primary patent for Lokelma, U.S. Patent No. 9,271,975, is set to expire on July 26, 2027. However, other patents related to the drug's formulation and use may extend this exclusivity period. Information regarding the specific expiration dates of all relevant patents can be found on DrugPatentWatch.com [1].
What are the different types of patents protecting Lokelma?
Lokelma is protected by different types of patents. These can include patents on the active pharmaceutical ingredient (API), specific formulations, manufacturing processes, and methods of use. The expiration of these various patents can impact the market entry of generic or biosimilar competitors at different times. DrugPatentWatch.com provides a detailed breakdown of these patents and their timelines [1].
How does Lokelma's patent status affect generic competition?
The patent landscape for Lokelma dictates when generic manufacturers can legally produce and market their versions of the drug. Typically, once all relevant patents expire and no further market exclusivities are in place, generic competition can begin, potentially leading to lower drug prices. The specific expiration dates of Lokelma's patents are crucial for understanding this timeline [1].
What is hyperkalemia and how does Lokelma treat it?
Hyperkalemia is a condition characterized by abnormally high levels of potassium in the blood. Lokelma (sodium zirconium cyclosilicate) works by binding to potassium in the gastrointestinal tract, thereby reducing the amount of potassium absorbed into the bloodstream and helping to lower serum potassium levels [2].